Silo Pharma Enters Into Exclusives License Agreement With Medspray Pharma BV For Intranasal Technology Used In SPC-15 Treatment For PTSD
Portfolio Pulse from Benzinga Newsdesk
Silo Pharma has entered into an exclusive license agreement with Medspray Pharma BV for intranasal technology to be used in SPC-15, a treatment for PTSD. This agreement could potentially enhance Silo Pharma's product offering and market position in the treatment of PTSD.
November 21, 2023 | 12:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silo Pharma's exclusive license agreement with Medspray Pharma for intranasal technology in SPC-15 treatment for PTSD may provide a competitive edge and expand its market reach.
The exclusive license agreement for intranasal technology is directly related to Silo Pharma's core business of developing therapies. This technology could be a key differentiator in the PTSD treatment market, potentially leading to increased investor interest and a positive impact on SILO's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100